The world's fastest LCMS/MS tandem mass spectrometer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The world's fastest LCMS/MS tandem mass spectrometer


Expanded range of ultra-fast, high-sensitivity applications

Shimadzu’s LCMS-8040 combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection.

A five-fold increase in sensitivity (reserpine, S/N ratio) has been achieved in comparison to the LCMS-8030 model by improving ion focusing and minimizing ion losses between multi-pole lenses.

The fastest scan speed of 15,000 u/s and the fastest polarity switching time of 15 msec, already known from the LCMS-8030, expand in combination with the higher sensitivity the potential range of LC/MS/MS applications. The LCMS-8040 achieves multiple reaction monitoring (MRM) transition speeds of up to 555 MRMs per second utilizing UFsweeper II collision cell technology. UFsweeper II features high-speed ion transport technology that maintains sensitivity and suppresses crosstalk, even for high-speed or simultaneous multi-component analyses.

LabSolutions LCMS software offers a variety of data processing features, including a Quantitation Browser which processes multiple analytes, and a Data Browser which allows users to analyze and compare multiple sets of data in the same window.

For more information please visit www.shimadzu.eu.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here